Navigation Links
More Fake Avastin Found in U.S., FDA Says
Date:4/4/2012

WEDNESDAY, April 4 (HealthDay News) -- The U.S. Food and Drug Administration says it has confirmed another counterfeit version of the cancer drug bevacizumab, most commonly known as Avastin, is being sold in the United States.

This time, the counterfeit product -- which the FDA says contains no active ingredient -- is posing as injectable Altuzan (bevacizumab) 400 mg/16ml, a Roche cancer medication that is approved for use in Turkey but not in the United States.

"Packaging or vials found in the U.S. that claim to be Roche's Altuzan with lot number B6021 should be considered counterfeit," the FDA said in a statement released Wednesday.

According to the FDA, medical practices got the fake Altuzan from "foreign sources" that include Richards Pharma (aka Richards Services), Warwick Healthcare Solutions or Ban Dune Marketing Inc (BDMI).

"Many, if not all of the products sold and distributed through this distributor have not been approved by the FDA," the agency said. The agency is urging all medical practices that believe they have received unapproved products from the three companies to "stop using [the products] and contact the FDA."

This is not the first time counterfeit Avastin has been spotted in the United States. In mid-February, Roche's Genetech unit warned of fake vials of Avastin. Later that month, the company said the fake drug was probably not harmful, but did not contain any active ingredient and so would be useless for people fighting cancer.

Doctors infuse Avastin to treat colon, lung, kidney and brain cancer.

According to the Associated Press, worldwide reports of drug counterfeiting have increased over the past 10 years.

More information

There's more on bevacizumab at the U.S. National Cancer Institute.

-- E.J. Mundell

SOURCES: U.S. Food and Drug Administration, news release, April 4, 2012; Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Avastin Largely Safe for Patients With Type of Advanced Lung Cancer
2. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
3. FDA Advises Against Avastin as Treatment for Breast Cancer
4. More Evidence Links Avastin to Heart Failure in Breast Cancer Patients
5. More Evidence Cancer Drug Avastin May Cause Harm
6. NIH study finds Avastin and Lucentis are equally effective in treating AMD
7. Cancer Drug Avastin Makes Inroads Against Ovarian Tumors
8. FDA Panel Rejects Avastin for Breast Cancer
9. Avastin Rejection Supported by Cancer Experts
10. Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
11. FDA Revokes Approval of Avastin for Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More Fake  Avastin Found in U.S., FDA Says
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
Breaking Medicine Technology: